Federal Agency Grant and Funding Opportunities related to the COVID-19 Outbreak

March 27, 2020

White House Office of Science and Technology Policy
COVID-19 High Performance Computing (HPC) Consortium
This consortium is a unique private-public effort to bring together federal government, industry, and academic leaders to execute complex computational research programs. Researchers are invited to submit COVID-19 related research proposals to the consortium via this online portal, which will then be reviewed for matching with computing resources from one of the partner institutions. An expert panel comprised of top scientists and computing researchers will work with proposers to assess the public health benefit of the work, with emphasis on projects that can ensure rapid results.
[XSEDE Website]

National Science Foundation
Important Notice to the Science and Engineering Community
NSF Implementation of OMB Memorandum M-20-17, entitled, “Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19) due to Loss of Operations.” The purpose of this guidance is to implement flexibilities from specific grant administrative, financial management, and audit requirements. (March 23, 2020)

National Science Foundation/Rapid Response Research (RAPID)
NSF is accepting COVID-19 proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to
inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge

- **Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)**

Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the **Computational and Data-Enabled Science and Engineering (CDS&E) program** or the **Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program**.

Proposals in response to this DCL and the NSF DCL on COVID-19 (NSF 20-052) may also request the use of NSF-funded advanced computing resources such as **Frontera, Stampede2, Bridges, Comet, and JetStream**.

- **Frequently Asked Questions for Proposers and Awardees**

**Health and Human Resources**

**HHS/Assistant Secretary for Preparedness and Response**

**Hospital Associations COVID-19 Preparedness and Response Activities**

Funding Opportunity: **EP-U3R-20-001**

Eligible entities include 53 hospital associations in all states. This NOFO will provide targeted awards to 53 hospital associations in all states, the District of Columbia, New York City, and Puerto Rico. Funding will be distributed to hospital associations using a formula specific to COVID-19, which takes into account criteria such as at-risk populations and other vulnerabilities associated with this pandemic (e.g., population density; size of populations with increased risk for mortality from COVID-19, such as older adults and individuals with comorbid health conditions; and health care capacity). Hospital associations will then distribute funds to hospitals and related health care entities within their state or jurisdiction, which may be used to train staff to implement pandemic preparedness plans to respond to COVID-19; procure supplies and equipment (with attention to supply chain shortages); rapidly ramp up infection control and triage training for health care professionals, especially considering growing supply chain shortages; retrofit separate areas to screen and treat large numbers of persons with suspected COVID-19 infections; implement expanded telemedicine and telehealth capabilities, and; increase the numbers of patient care beds to provide surge capacity using temporary structures, such as temporary hospitals that are deployed in a pandemic. (March 24, 2020)
HHS/Centers for Disease Control – OSTLTS
Supplemental: Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health
Funding Opportunity Number: CDC-RFA-OT18-18020202SUPP20
CDC announces the availability of supplemental funding for the organizations that were previously awarded funding under Funding Strategy 1 of CDC-RFA-OT18-1802: "Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health" in FY18. 2) Organizations meeting this criteria are eligible to apply for new CIO Project Plans specifically intended to address the current outbreak of COVID-19, and may apply according to the Target Population Category (A, B, or C) and Target Population for which they received initial funding in FY18.3) Link: grants.gov Search on funding number CDC-RFA-OT18-18020202SUPP20

HHS/Centers for Disease Control - OSTLTS
COVID-19 Response Supplement: Tribal Public Health Capacity-Building and Quality Improvement Umbrella Cooperative Agreement
Funding Opportunity Number: CDC-RFA-OT18-18030202SUPP20
Eligible Applicants: Native American tribal governments. Emergency supplemental funding to prevent, prepare for, and respond to COVID-19 for the American Indian/Alaska Native (AI/AN) tribal nations and regional AI/AN tribal organizations that were previously awarded funding. (March 24, 2020)

Food and Drug Administration/Office of the Chief Scientist (OCS) and Center for Drug Evaluation and Research (CDER), Office of Medical Policy (OMP)
Drug Development Science Support (U01)
Funding Opportunity Number: FOR-FD-20-010
Announces the intent to release a grant to protect and promote the health of the American public by creating new, applied scientific knowledge, tools, standards and approaches to evaluate products more effectively, predictably and efficiently. NOTE: This is a Forecased Opportunity. Estimated start date: Sept 01, 2020.

HHS/Biomedical Advanced Research and Development Authority (BARDA)
Updated a broad agency announcement (BAA) to solicit proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals. BARDA will provide funding, as well as expertise and core services to support development projects selected through this BAA. These products include diagnostic tests (assays); vaccines; therapeutics; medications to help regulate or normalize the immune system (immunomodulators); therapeutics targeting lung repair; medicines that prevent infections either before or after exposure to the virus (pre-exposure or post-exposure prophylaxis); respiratory protective devices; and ventilators. BAA-18-100-SOL-00003-Amendment 13 (March 4, 2020)

HHS/Biomedical Advanced Research and Development Authority (BARDA)
BARDA opened an easy broad agency announcement, an EZ-BAA, seeking diagnostics that utilize platforms already cleared by the FDA, with a viable plan to meet requirements for the FDA to consider emergency use authorization within 12 weeks.
HHS/Office of the Assistant Secretary for Preparedness and Response (ASPR)
Public Health Emergency development of new medical countermeasures

HHS/Centers for Disease Control and Prevention (CDC)
Funding to provide resources to state and local jurisdictions in the coronavirus disease 2019 (COVID-19) response. CDC is contacting State Health Officers to move forward with awarding over $560 million to states, localities, territories, and tribes. CDC will use existing networks to reach out to state and local jurisdictions to access this initial funding. Listing of funding to jurisdictions here.

HHS/Health Resource and Administration
Frequently Asked Questions for health centers regarding Novel Coronavirus (COVID-19)

National Institutes of Health
NIH Funding Opportunities Specific to COVID-19 here.

NIH/National Institute of General Medical Sciences
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (March 25, 2020)
Notice Number: NOT-GM-20-025
NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:

- Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
- Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
- Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).

NIH/National Institute of Allergy and Infectious Diseases (NIAID)
Emergency Supplement Notice of Special Interest (NOSI) Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
Funding Number: NOT-AI-20-034
NIAID is encouraging the submission of applications for Competitive Revisions to active grants. NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. (March 25, 2020)
**NIH/National Center for Advancing Translational Sciences (NCATS)**

**Notice of Special Interest (NOSI) : Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need**

**Funding Number:** NOT-TR-20-011

NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337). (March 24, 2020)

NIH Small Business Program Office: COVID-19 Update for Small Businesses Webinar
To be held March 30, 2020 at 11am-12am EST. Please join to learn how SBPO is dealing with the COVID-19 pandemic and how your business can engage with the NIH during this time. *Register via [https://www.surveymonkey.com/r/2YNBCT7](https://www.surveymonkey.com/r/2YNBCT7)*

**NIH/National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences (NIGMS)**

**Administrative Supplementals**
Current grantees may be eligible to apply for an administrative supplemental. Contact your program officer to discuss proposed research on SARS-CoV-2/COVID-2019. If it is within the scope of your current grant, an administrative supplement is the best option to obtain additional funding. [PA-18-591](#)

**NIH/National Institute of Allergy and Infectious Diseases (NIAID) and National Institute of General Medical Sciences (NIGMS)**

**Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)**

**Notice Number:** NOT-AI-20-030

NIAID and NIGMS are collaborating to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV.

**NIH/National Heart, Lung, and Blood Institute**

NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative...
agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Notice Number: NOT-HL-20-757
Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

NIH/National Institute on Drug Abuse (NIDA)
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Notice Number: NOT-DA-20-047
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. (March 19, 2020)

National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus Resources for Researchers

National Institutes of Health/Office of The Director
Given the fact that COVID-19 and associated impacts continue to evolve, applicants and recipients are strongly encouraged to monitor NIH website for updates.

General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19
NIH intends to publish detailed guidance related to administrative flexibilities and associated FAQs.
Notice Number: NOT-OD-20-083

NIH/Fogarty International Center
Coronavirus news, funding and resources for global health researchers

NIH Research
Examples of coronavirus research supported by NIH

World Health Organization
World scientists on COVID-19 met at the World Health Organization’s Geneva headquarters in February 2020 to assess the current level of knowledge about the new virus, agree on critical research questions that need to be answered urgently, and ways to work together to accelerate and fund priority research that can contribute to curtail this outbreak and prepare for future outbreaks. R&D Blueprint

Department of Energy
COVID-19 Rapid Research Response
DOE is soliciting ideas about how the Department and the National Laboratories might contribute resources for science and technology efforts and collaborations. The Department is encouraging the scientific community and others to consider research questions that underpin COVID-19 response and is requesting input on strategic, priority research directions that may be undertaken using DOE user facilities, computational resources, and enabling infrastructure.

Dear Colleague

DOE Resources Supporting Coronavirus Research

Department of Defense
Defense Logistics Agency (DLA) Troop Support Clothing & Textiles Directorate
Request for Information for PPE in response to COVID-19
Notice ID: SPE1C1-20-R-COVID19
DLA is conducting market research to determine industry capabilities for providing Personal Protective Equipment (PPE) against viral contamination, specifically COVID-19. This is a Request for Information only and not a solicitation for award. (March 20, 2020)

Updated: Medical Technology Enterprise Consortium released Request for Project Proposals (RPP) for prototypes of medical and information technologies to combat Covid-19.
Notice ID: MTEC-solicitation-COVID-19
FOCUS AREA: Therapeutic(s) that can treat COVID-19. Treatments with potential application to the prevention of COVID-19 infection are desired. Therapeutics that can be administered in a non-hospital environment are desired. (March 25, 2020)

Defense/Army Medical Research Acquisition Activity (USAMRAA)
USAMRAA’s COVID-19 FAQs
This notice addresses general questions associated with proposal submission and award management that may arise in relation to COVID-19. These FAQs will be updated here as more information becomes available

Department of Homeland Security
Homeland Security/Science and Technology Directorate
Press release: Crucial Research to Mitigate COVID-19 (March 25, 2020)

TSA Industry Assistance with COVID-19
Notice ID: 2020-TSA-IndustryNotice
In the current climate TSA appreciates industry offering to assist the Agency in response to COVID-19. Please submit your offering to the Contracting and Procurement office point of contact, Evelyn S. Tyndell at EngageProcurement@tsa.dhs.gov to ensure appropriate handling.
Department of Justice
DOJ/Office of Community Oriented Policing Services Office (COPS)
COPS has extended the solicitation deadline for several open grant programs due to the potential impact of jurisdictional emergency responses to COVID-19 that may cause reasonable delays for applicants. For detailed individual program information, see the grants page.

DOJ/Office of Justice Programs
OJP announced that solicitations with application due dates before April 1st will have a 2 week extension for submission. OJP Grantee Update #1 COVID-19 Impacts